SPOTLIGHT: Andrx struggles with quality questions

September 29, 2005 — 8:01pm ET

ALSO NOTED: Analysts predict trouble for second-gen Rituxan; Sucampo earns $50M on FDA approval;and much more...
Pfizer gets new cancer team to advance key drugs
Spectrum sells off generic drugs
SPOTLIGHT: Watson extends merger deadline
Watson to pay $1.9B for Andrx
ALSO NOTED: Neurologix touts Phase I results; QLT CEO resigns; BioLineRx gains $9M in new funding; FDA to miss action date on H
Andrx applications put on hold as feds review manufacturing
Report: Pfizer makes counter-offer for Ranbaxy
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
ALSO NOTED: GSK releases new Cervarix data; FDA mulls DTC ads; and much more...

Tools

Email
Print
Contact Author

The Miami Herald profiles Andrx, a generic drug maker which has run afoul of the FDA. Andrx specializes in complex generics, but the FDA wants to see its quality controls improved before they will approve any of its 30 outstanding drug applications. Feature

Paid Research Reports

RNA therapy: the next big thing after monoclonal antibodies?
Biotech M&A Strategies: Deal assessments, trends and future prospects
The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
Sales Force Effectiveness
Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage

More Research Reports >>

Most Popular Stories

Featured Jobs

Webinars

Popular Topics

Events

SPOTLIGHT: Andrx struggles with quality questions

Related Stories

Paid Research Reports

THE FIERCEMARKETS NETWORK